American Society of Clinical Oncology 41st Annual Meeting

Bibliography

• SANDLER AB, GRAY R, BRAHMER J et al.: Randomized Phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer: an Eastern Cooperative Oncology Group Trial-E4599. j Clin. Oncol. (2005) 23(16S part 2):1090s. [abstract #4]. ASCO plenary paper; a large randomised trial likely to change the standard of care.
   Google Scholar
• GIANTONIO BJ, CATALANO PJ, MEROPOL NJ et al.: High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E200. j ain. Oncol (2005) 23(16S part 1):1s. [abstract #2]. ASCO plenary paper; a large randomised trial confirming a change in the standard of care.
   Google Scholar
• WOLMARK N, WIEAND HS, KUEBLER JP et al.: A Phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP protocol C-07. J. ain. Oncol (2005) 23(16S part 2):1092s. [abstract #3500].
   Google Scholar
• •Randomised trial that may change the standard of care.
   Google Scholar
• HOCHSTER HS, WELLES L, HART L et al.: Safety and efficacy of bevacizumab when added to oxaliplatin/fluoropyrimidine regimens as first-line treatment of metastatic colorectal cancer: TREE 1 & 2 studies. J. ain. Oncol. (2005) 23(16S part 1):248s. [abstract #3].
   Google Scholar
• ••ASCO plenary paper; a large randomisedtrial confirming a change in the standard of care.
   Google Scholar
• SHAH MA, ILSON D, RAMANATHAN RK et al.: A multicenter Phase II study of inrinotecan, cisplatin, and bevacizumab in patients with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. J. ain. Oncol (2005) 23(16S part 1):314s. [abstract #4025].
   Google Scholar
• STOPECK AT, BELLAMY W, UNGER J et al.: Phase II trial of single agent bevacizumab inpatients with relapsed, aggressive non-Hodgkin's lymphoma: Southwest Oncology Group study S0108. J. ain. Oncol. (2005) 23(16S part 1):583s. [abstract #6592].
   Google Scholar
• IMRIE K, BELCH A. PETTENGELL R et al.: Rituximab plus CVP chemotherapy versus CVP alone as first-line treatment for follicular lymphoma: treatment effect according to baseline prognostic factors. J. ain. Oncol. (2005) 23(16S part 1):566s. [abstract #6525].
   Google Scholar
• DREYLING MH, FORSTPOINTNER R, LUDWIG WD et al.: Combined immuno-chemotherapy (R-FCM) results in superior remission rates and overall survival in recurrent follicular and mangle cell lymphoma: follow up of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J. ain. Oncol (2005) 23(16S part 1):567s. [abstract #6528].
   Google Scholar
• HIDDEMANN W, FORSTPOINTNER R, DREYLING M et al.: Rituximab maintenance following a rituximab containing chemotherapy significantly prolongs the duration of resonse in patients with relapsed follicular and mantle cell lymphomas: results of a prospective randomzied trial of the German Low Grade Lymphoma Study Group. ain. Oncol (2005) 23(16S part 1):566s. [abstract #6527].
   Google Scholar
• PFREUNDSCHUH MG, HO A, WOLF M et al.: Treatment results of CHOP-21, CHOEP-21, MACOP-B, and PMitCEBO with and without rituximab in young good-prognosis patients with aggressive lymphomas: rituximab as an 'equalizer' in the MinT study./ ain. Oncol (2005) 23(16S part 1):567s. [abstract #6529].
   Google Scholar
• PEREZ EA, SUMAN VJ, DAVIDSON NE et al.: Interim cardiac safety analysis of NCCTG N9831 intergroup adjuvant trastuzumab trial. J. ain. Oncol (2005) 23(16S part 1):17s. [abstract #556].
   Google Scholar
• EXTRA JM, COAGNETTI F, MARANINCHI D et al.: Long-term survival demonstrated with trastuzumab plus docetaxel: 24-month data from a randomized trial (M77001) in HER2-positive metastatic breast cancer. ain. Oncol (2005) 23(16S part 1):17s. [abstract #555].
   Google Scholar
• LIGGETT WH, HAINSWORTH JD, SPIGEL DR et al.: Fludarabine/rituximab followed by alemtuzumab as first-line tretment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a Minni Pearl Cancer Research Network Phase II trial. J. ain. Oncol (2005) 23(16S part 1):574s. [abstract #6556].
   Google Scholar
• ENGERT A, ELTER T, BORCHMANN P et al.: Concomitant treatment of patients with relapsed/refractory CLL using a combination of fludarabine and alemtuzumab is highly effective: final results of a phase-II study. J. ain. Oncol (2005) 23(16S part 1):574s. [abstract #6558].
   Google Scholar
• SPITZER G, ZACKON I, STELLA P et al.: Anti-epidermal growth factor antibody, cetuximab, in patients with stage IV colorectal carcinoma who failed all standard therapy: final report of an access protocol. J. ain. Oncol (2005) 23(16S part 1):282s. [abstract #3646].
   Google Scholar
• LENZ HJ, MAYER RJ, MIRTSCHING R et al.: Consistent response to treatment with cetuximab monotherapy in patients with metastatic colorectal cancer. J. ain. Oncol. (2005) 23(16S part 1):255s. [abstract #3536].
   Google Scholar
• RUBIO ED, TABERNERO J, VAN CUTSEM E et al.: Cetuximab in combination with oxaliplatin/5-fluoruracil/ folinic acid (FOLFOX-4) in the first line treatment of patients with epidermal growth factor receptor-expressing metastatic colorectal cancer: an internal Phase II study. ain. Oncol. (2005) 23(16S part 1):254s. [abstract #3535].
   Google Scholar
• POLIKOFF J, MITCHELL EP, BADARINATH S et al.: Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): preliminary efficacy analysis of a randomized Phase III trial. J. ain. Oncol (2005) 23(16S part 1):264s. [abstract #3574].
   Google Scholar
• SALTZ LB, LENZ HJ, HOCHSTER H et al.: Randomized Phase II trial of cetuximab/bevacizumab/irinotecan versus cetuximab/bevacizumab in irinotecan-refractory colorectal cancer. J. ain. Oncol (2005) 23(16S part 1):248s. [abstract #3508].
   Google Scholar
• SCHILDER RJ, EMMANOUILIDES C, VO K et al.: Yttrium 90 ibritumomab tiuxetan is safe and effective in older patients with relapsed refractory NHL. ain. Oncol. (2005) 23(16S part 1):575s. [abstract #6562].
   Google Scholar
• KAMINSKI MS, COLEMAN M, LINK BK et al.: Tositumomab and iodine 1131 tositumomab: efficacy and safety in 141 patients with previously untreated low-grade non-Hodgkin's lymphoma. ain. Oncol. (2005) 23(16S part 1):575s. [abstract #6560].
   Google Scholar
• GREGORY SA, LEONARD JP, VOSE JM et al.: Superior outcomes associated with earlier use: experience with tositumomab iodine 1131 tositumomab in 1,177 patients with low-grade, follicular, and transformed non-Hodgkin's lymphoma. J. ain. Oncol (2005) 23(16S part 1):575s. [abstract #6561].
   Google Scholar
• SHIPLEY DL, GRECTO FA, SPIGEL DR et al.: Rituximab with short duration chemotherapy followed by "Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: update of a Minnie Pearl Cancer Research network Phase II trial. J. ain. Oncol (2005) 23(16S part 1):579s. [abstract #6577].
   Google Scholar
• ALLISON DE, NG C, DERYNCK MK et al.: Pharmacokinetics of pertuzumab (rhuMAb 2C4) in Phase II studies of ovarian, breast, prostate, and lung cancers. Clin. Oncol. (2005) 23(16S part 1):173s. [abstract #2532].
   Google Scholar
• JANIK JE, MORRIS JC, STETLER-STEVENSON M et al.: Phase I trial of siplizumab in CD2-positive lymphoproliferative disease. J. Clin. Oncol. (2005) 23(16S part 1):174s. [abstract #2533].
   Google Scholar
• BLOHMER J, GORE M, KUEMMEL S et al.: Phase II study to determine response rate, pharmacokinetics, pharmacodynamics, safety, and tolerability of treatment with the humanized anti-epidermal growth factor receptor monoclonal antibody EMD72000 (matuzumab) in patients with recurrent cervical cancer. J. Clin. Oncol. (2005) 23(16S part 1):174s. [abstract #2534].
   Google Scholar
• MALIK I, HECHT JR, PATNAIK A et ell.: Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer. J. Clin. Oncol. (2005) 23(16S part 1):251s. [abstract #3520].
   Google Scholar
• FORERO A, BERNSTEIN S, GOPAL A et al.: Initial Phase II results of SGN-30 (anti-CD30 monoclonal antibody) in patients with refractory or recurrent systemic anaplastic large cell lymphoma. Clin. Oncol. (2005) 23(16S part 1):585s. [abstract #6601].
   Google Scholar
• HUSSEIN MA, BERENSON JR, NIESVIZKY R et ell.: Phase I trial of a humanized anti-CD40 monoclonal antibody (SGN-40) in the treatment of multiple myeloma. J. Clin. Oncol. (2005) 23(16S part 1):580s. [abstract #6581].
   Google Scholar
• DRACHMAN JG, LAW CL, FURMAN RR et al.: A humanized anti-CD40 monoclonal antibody (SGN-40) demonstrates antitumor activity in non-Hodgkin's lymphoma: initiation of a Phase I clinical trial. J. Clin. Oncol. (2005) 23(16S part 1):578s. [abstract #6572].
   Google Scholar
• FISCHKOFF SA, HERSH E, WEBER J et al.: Durable and long-term progression-free survival observed in a Phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma. J. Clin. Oncol. (2005) 23(16S part 1):516s. [abstract #7525].
   Google Scholar
• YANG JC, BECK KE, BLANSFIELD JA et al.: Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX-010)J. Clin. Oncol. (2005) 23(16S part 1):166s. [abstract #2501].
   Google Scholar
• CORTES J, GILES F, SALVADO A et al.: High-dose imatinib in patients with previously untreated chronic myeloid leukemia (CML) in early chronic phase: preliminary results of a multicenter community based trial. J. Clin. OncoL (2005) 23(16S part 1):564s. [abstract #6518].
   Google Scholar
• HEINRICH MC, SHOEMAKER JS, CORLESS CL et al.: Correlation of target kinase genotype with cinical activity of imatinib mesylate in patients with metastatic GI stromal tumors (GIST) expressing KIT. Clin. Oncol. (2005) 23(16S part 1):3s. [abstract #7] .
   Google Scholar
• •ASCO plenary paper providing insights into the mechanism of imatinib resistance.
   Google Scholar
• DEMATTEO RP, ANTONESCU CR, CHADARAM Vet al.: Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST): safety results from the US Intergroup Phase II trial ACOSOG Z9000. J. Clin. Oncol. (2005) 23(16S part 1):818s. [abstract #9009].
   Google Scholar
• CASALI PG, STACCHIOTTI S, MESSINA A et al.: Imatinib mesylate in 18 advanced chordoma patients. J. Clin. OncoL (2005) 23(16S part 1):819s. [abstract #9012].
   Google Scholar
• •Promising activity in an uncommon disease for which there is no effective systemic therapy.
   Google Scholar
• TALPAZ M, KANTARJIAN HM, PAQUETTE R et al.: A Phase I study of BMS-354825 in patients with imatinib-resistant and intolerant chronic phase chronic myeloid leukemia (CML): results form CA180002. J. Clin. Oncol. (2005) 23(16S part 1):564s. [abstract #6519].
   Google Scholar
• SAWYERS CL, SHAH NP, KANTARJIAN HM et al.: A Phase I study of BMS-354825 in patients with imatnib-resistant and intolerant accelerated and blast phase chronic myeloid leukemia (CML): results from CA180002. J. Clin. Oncol. (2005) 23(16S part 1):565s. [abstract #6520].
   Google Scholar
• SHAH N, SAWYERS CL, KANTARJIAN HM et al.: Correlation of clinical response to BMS-354825 with BCR-ABL mutation status in imatinib-resistant patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-associated acute lymphoblastic leukemia. Clin. Oncol. (2005) 23(16S part 1):565s. [abstract #6521].
   Google Scholar
• •This paper shows that most mutations associated with imatinib-resistant disease are overcome with this agent.
   Google Scholar
• MACHI RG, FLETCHER JA, HEINRICH MC et al.: Results from a continuation trial of SU11248 in patients with imatinib-resistant gastgrointestinal stromal tumor (GIST). J. Clin. Oncol. (2005) 23(16S part 1):818s.\ [abstract #9011].
   Google Scholar
• VAN DEN ABBEELE A, MELENEVSKY Y, DE VRIES D et al.: Imaging kinase target inhibition with SU11248 by FDG-PET in patients with imatinib-resistant gastrointestinal stromal tumors. J. Clin. Oncol. (2005) 23(16S part 1):817s. [abstract #9006].
   Google Scholar
• MOTZER RJ, RINI GI, MICHAELSON MD et al.: Phase II trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma. J. Clin. Oncol. (2005) 23(16S part 1):380s. [abstract #4508].
   Google Scholar
• •Promising single-agent results in cancer that needs better systemic therapy.
   Google Scholar
• MILLER KD, BURSTEIN HJ, ELIAS AD et al.: Phase II study of 5U11248, a multitargeted receptor tyrosine kinase inhibitor in patients with previously treated metastatic breast cancer. J. Clin. Oncol. (2005) 23(16S part 1):19s. [abstract #563].
   Google Scholar
• BEZJAK A, SHEPHERD F, TU D et al.: Symptom response in non-small cell lung cancer patients treated with erlotinib: quality of life analysis of the NCIC CTG BR.21 trial. J. Clin. Oncol. (2005) 23(16S part 1):625s. [abstract #7018].
   Google Scholar
• MOORE MJ, GOLDSTEIN D, HAMM J et al.: Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. J. Clin. Oncol. (2005) 23(16S part 1): ls. [abstract #1].
   Google Scholar
• •ASCO plenary paper; likely to change the standard of care for advanced pancreatic cancer, as this is the first agent to add to the benefit of gemcitabine.
   Google Scholar
• CLOUGHESY T, YUNG A, VRENDENBERG Jet al.: Phase II study of erlotinib in recurrent GBM: molecular predictors of outcome. J. Clin. Oncol. (2005) 23(16S part 1):115s. [abstract #1507].
   Google Scholar
• VOKES EE, COHEN EW, MAUER AM et al.: A Phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. (2005) 23(16S part 1):501s. [abstract #5504].
   Google Scholar
• TSAO AS, HERBST R, SANDLER A et aL: Phase I/II trial of bevacizumab plus erlotinib for patients with recurrent non-small cell lung cancer: correlation of treatment response with mutations of the EGFR tyrosine kinase gene. J. Clin. Oncol. (2005) 23(16S part 1):501s. [abstract #7092].
   Google Scholar
• CUFER T, VRDOLJAK E: Results from a Phase II, open-label, randomized study (SIGN) comparing gefitinib with docetaxel as second-line therapy in patients with advanced (stage Mb or IV) non-small-cell lung cancer. J. Clin. Oncol (2005) 23(16S part 1):629s. [abstract #7035].
   Google Scholar
• ESCUDIER B, SZCZYLIK C, EISEN T et al.: Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma. J. Clin. Oncol (2005) 23(16S part 2), 1093s [abstract #4510].
   Google Scholar
• ••May become the first agent to improvesurvival in a randomised trial in metastatic renal cell cancer.
   Google Scholar
• EISEN T, AHMAD T, GORE ME et ell.: Phase I trial of BAY 43–9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients. J. Clin. Oncol (2005) 23(16S part 1):712s. [abstract #7508].
   Google Scholar
• STORNIOLO AM, BURRIS H, PEGRAM M et al.: A Phase I, open-label study of lapatinib (GW572016) plus trastuzumab: a clinically active regimen. J. Clin. Oncol. (2005) 23(16S part 1):18s. [abstract #559].
   Google Scholar
• RINI B, RIXE O, BUKOWSKI R et al.: AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase II study of cytokine-refractory, metastatic renal cell cancer. J. Clin. Oncol. (2005) 23(16S part 1):380s. [abstract #4509].
   Google Scholar
• •Promising single-agent results in a cancer that needs better systemic therapy.
   Google Scholar
• HECHT JR, TRARBACH T, JAEGER E et al.: A randomized, double-blind placebo-controlled, Phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1).f Clin. Oncol. (2005) 23(16S part 2):1090s. [abstract #3].
   Google Scholar
• •ASCO plenary paper; benefit of this small molecule antiangiogenesis agent did not quite reach statistical significance.
   Google Scholar
• MOSCHOS SJ, EDINGTON HD, RAO UN et al.: High dose interferon-a2b: toxicity, response, and predictive markers in a neoadjuvant trial for regional lymph node metastatic melanoma. J. Clin. Oncol (2005) 23(16S part 1):714s. [abstract #7517].
   Google Scholar
• NEGRIER S, PEROL D, RAVAUD A et al.: Do cytokines improve survival in patients with metastatic renal cell carcinoma of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. J. Clin. Oncol (2005) 23(16S part 2):1093s. [abstract #4511].
   Google Scholar
• O'DAY S, ATKINS M, WEBER J et al.: A Phase II multi-center trial of maintenance biotherapy after induction concurrent biochemotherapy for patients with metastatic melanoma. J. Clin. Oncol (2005) 23(16S part 1):710s. [abstract #7503].
   Google Scholar
• WEBER JS, SNIVELY J, STAN S et al.: Randomized Phase II trial of melanoma peptides with Montanide ISA 51 and different doses of IL-12 with alum for resected stages IIC/III and IV melanoma. Clin. Oncol (2005) 23(16S part 1):167s. [abstract #2506].
   Google Scholar
• KOCH KM, ROMAN JR, JAWORSKI D et al.: PK and PD of recombinant human IL-18 administered IV in repeated cycles to patients with solid tumors. J. Clin. Oncol (2005) 23(16S part 1):174s. [abstract #2535].
   Google Scholar
• CURTI BD, REDMAN BG, THOMPSON JA et al.: Preliminary tolerability and anti-tumor activity of intravenous recombinant human interleukin-21 (IL-21) in patients with metastatic melanoma and metastatic renal cell carcinoma. J. Clin. Oncol. (2005) 23(16S part 1):166s. [abstract #2502].
   Google Scholar
• SMALL EJ, SCHELLHAMMER PF, HIGANO CS et al.: Results of a placebo-controlled Phase III trial of immunotherapy with APC8015 for patients with hormone refractory prostate cancer. J. Clin. Oncol (2005) 23(16S part 1):378s. [abstract #4500].
   Google Scholar
• •First vaccine trial to suggest a survival benefit in prostate cancer, but study size and other results raise questions about the validity of the observation.
   Google Scholar
• GULLEY JL, TODD N, DAHUT W et aL: A Phase II study of PROSTVAC-VF vaccine, and the role of GM-CSF, in patients with metastatic androgen insensitive prostate cancer. J. Clin. Oncol (2005) 23(16S part 1):166s. [abstract #2504].
   Google Scholar
• SIMONS JW, HIGANO C, SMITH D et al.: Clinical and immunologic findings in a Phase II study of a GM-CSF secreting prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer. J. Clin. Oncol (2005) 23(16S part 1):170s. [abstract #2517].
   Google Scholar
• DREICER R, AHMAN R, PANTUCK A et al.: Vaccine immunotherapy with MVA-muc-1-1L2 (TG4010) in prostate cancer patients with biochemical failure. Clin. Oncol. (2005) 23(16S part 1):382s. [abstract #4518].
   Google Scholar
• THOMPSON P, FISHMAN M, SEIGNE J et al: Phase II study of B7-1 gene-modified autologous tumor cell vaccine and subcutaneous IL-2 for patients with stage IV renal cell carcinoma. J. Clin. Oncol (2005) 23(16S part 1):378s. [abstract #4502].
   Google Scholar
• IBRAHIM RA, ACHTAR MS, HERRIN VE et al.: Autologous PBMCs pulsed with HPV16 E6 as an immunotherapeutic agent for patients with advanced cervical cancer. J. Clin. Oncol (2005) 23(16S part 1):167s. [abstract #2508].
   Google Scholar
• ACHTER MS, IBRAHIM R, HERRIN VE et al.: Pre-immature dendritic cells pulsed with human papillomavirus 16 E7 peptide vaccine in advanced cervical cancer. J. Clin. Oncol (2005) 23(16S part 1):171s. [abstract #2522].
   Google Scholar
• NESSELHUT T, MATTHES C, MARX D et al.: Cancer therapy with immature monocyte-derived dendritic cells in patients with advanced breast cancer. J. Clin. Oncol (2005) 23(16S part 1):172s. [abstract #2528].
   Google Scholar
• GRIBBEN JB, STEPHENSON JJ, BARTLETT NL et al.: A Phase II study of Xcellerated T cells in patients with relapsed or refractory indolent non-Hodgkin's lymphoma. J. Clin. Oncol (2005) 23(16S part 1):168s. [abstract #2510].
   Google Scholar
• KIPPS TJ, WIERDA WG, CASTRO JE et al.: A Phase I/II study of Xcellerated T cells in patients with chronic lymphocytic leukemia. J. Clin. Oncol (2005) 23(16S part 1):168s. [abstract #2511].
   Google Scholar
• KIRKWOOD JM, BEDIKIAN AY, MILLWARD MJ et al.: Long-term survival results of a randomized multinational Phase III trial of dacarbazine (DTIC) with or without Bc1-2 antisense (oblimersen sodium) in patients with advanced malignant melanoma. J. Clin. Oncol (2005) 23(16S part 1):711s. [abstract #7506].
   Google Scholar
• BLUMENSCHEIN GR, KHURI F, GATZEMEIER U et al.: A randomized Phase III trial comparing bexarotene/ carboplatin/paclitaxel versus carboplatin/ paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer. J. Clin. Oncol (2005) 23(16S part 2):1094s. [abstract #7001].
   Google Scholar
• •Retinoids fail again in a large US randomised trial in lung cancer.
   Google Scholar
• JASSEM J, ZATLOUKAL P, RAMLAU R et al.: A randomized Phase III trial comparing bexarotene/cisplatin/vinorelbine versus cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer. Clin. Oncol (2005) 23(16S part 2):1095s. [abstract #7024].
   Google Scholar
• •Retinoids fail again in a large European randomised trial in lung cancer.
   Google Scholar
• RICHTIG E, SOYER HP, POSCH M et al.: Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant combination therapy of interferon alfa and isotretinoin with adjuvant therapy of interferon alfa in patients with primary melanoma in stage IIA and JIB AJCC/UICC 1988. J. Clin. Oncol (2005) 23(16S part 1):713s. [abstract #7515].
   Google Scholar
• LIST AF, DEWALD G, BENNETT Jet al.: Hematologic and cytogenetic response to lenalidomide (CC-5013) in patients with transfusion-dependent myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: results of the multicenter MDS-003 study. J. Clin. Oncol (2005) 23(16S part 1):2s. [abstract #5].
   Google Scholar
• ••ASCO plenary paper; agent will probably beapproved as treatment for myelodysplasia.
   Google Scholar
• RAJKUMAR SV, DINGLI D, NOWAKOWSKI G et al.: Thaldiomide and dexamethasone in newly diagnosed mulitple myeloma: long-term results in patients not undergoing upfront autologous stem cell transplantation. J. Clin. Oncol (2005) 23(16S part 1):593s. [abstract #6632].
   Google Scholar
• MILLER KC, CZUCZMAN MS, DIMICELI Let al.: Antileukemia effects of novel immunomodulatory agent lenalinomide with or without rituximab inpatients with relapsed or refractory chronic lymphocytic leukemia. Encouraging preliminary results of ongoing Phase II clinical study. J. Clin. Oncol (2005) 23(16S part 1):574s. [abstract #6557].
   Google Scholar
• LUDWIG H, DRACH J, TOTHOVA E et al.: Thalidomide-dexamethasone versus melphalan-prednisolone as first line treatment in elderly patients with multiple myeloma. j Clin. Oncol. (2005) 23(16S part 1):569s. [abstract #6537].
   Google Scholar
• KNISELY JPS, BERKEY BA, CHAKRAVARTI A et ell.: RTOG 0118: a Phase III study of conventional radiation therapy alone versus conventional radiation therapy plus thalidomide for multiple brain metastases. J. Clin. Oncol (2005) 23(16S part 1):114s. [abstract #1500].
   Google Scholar
• PUDUVALLI VK, GIGLIO P, GROVES MD et al.: Phase II trial of thalidomide in combination with irinotecan in adults with recurrent glioblastoma multiforme. j Clin. Oncol (2005) 23(16S part 1):120s. [abstract #1524].
   Google Scholar
• RICHARDSON PG, SONNEVELD P, SCHUSTER MW et al.: Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed myeloma. Clin. Oncol (2005) 23(16S part 1):568s. [abstract #6533].
   Google Scholar
• GOY A, BERNSTEIN S, KAHL B et al.: Bortezomib in patients with relapsed or refractory mantle cell lymphoma: preliminary results of the PINNACLE study. J. Clin. Oncol (2005) 23(16S part 1):575s. [abstract #6563].
   Google Scholar
• FANUCCHI MP, FOSSELLA F, FIDIAS P et al.: Bortezombib ± docetaxel in previously treated patients with advanced non-small cell lung cancer: a Phase II study. J. Clin. Oncol (2005) 23(16S part 1):629s. [abstract #7034].
   Google Scholar
• KOCHHAR R, KHURANA BEJJANKI HR, CALDITO G, FORT C: Statins to reduce breast cancer risk: a case control study in US female veterans. Clin. Oncol (2005) 23(16S part 1):7s. [abstract #514].
   Google Scholar
• KHURANA V KOCCHAR R, JEJJANKI HR, CALDITO G, FORT C: Statins reduce the incidence of lung cancer: a study of half a million US veterans. Clin. Oncol (2005) 23(16S part 1):107s. [abstract #1006].
   Google Scholar
• SINGAI R, KHURANA V, CALDITO G, FORT C: Statins and prostate cancer risk: a large case control study in veterans. J. Clin. Oncol (2005) 23(16S part 1):107s. [abstract #1004].
   Google Scholar